HK Stock Market Move | GIANT BIOGENE (02367) rose by over 4% during trading. Recently, its three categories of medical devices, including "Cross-linked Recombinant Collagen Filler", have been approved.

Giant Biogene (02367) rose more than 4% during the day, and as of press time, it had risen 2.4% to HK$25.56, with a turnover of HK$46.32 million. On the news front, recently, Giant Biogene announced that its wholly-owned subsidiary, Shaanxi Giant Biogene Technology Co., Ltd., has received the "Medical Device Registration Certificate of the People's Republic of China" issued by China National Medical Products Administration for cross-linked recombinant collagen protein implants. This product uses the full-length sequence of human type III mature collagen protein, which consists of a total of 1,068 amino acids, fully retaining the natural functional domains of collagen protein, and adopts a physical cross-linking process without the risk of chemical cross-linking agent residue, forming a stable three-dimensional network gel for injection and filling in the dermis of the neck to correct moderate to severe neck wrinkles. CICC pointed out that Giant Biogene's three categories of medical devices, including the "cross-linked recombinant collagen protein filler," have been approved. This product is the world's first cross-linked recombinant type III full-length sequence collagen protein filler for neck wrinkle indication, with outstanding differentiation advantages. At the same time, the company's first approved medical beauty product was officially launched on June 9th, and the trend of accelerating margin improvement in the cosmetics business is evident. It is optimistic about the company's improving fundamentals and recommends paying attention to opportunities for bottom layout.